World Health Organ Tech Rep Ser. 2016(999):1-267.
This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the adoption of international recommendations for the production and control of vaccines and other biological substances, and the establishment of international biological reference materials. Following a brief introduction, the report summarizes a number of general issues brought to the attention of the Committee. The next part of the report, of particular relevance to manufacturers and national regulatory authorities, outlines the discussions held on the development and adoption of new and revised WHO Recommendations, Guidelines and guidance documents. Following these discussions, a WHO guidance document on Regulatory assessment of approved rDNA-derived biotherapeutics was adopted along with WHO Guidelines on the stability evaluation of vaccines for use under extended controlled temperature conditions and on WHO good manufacturing practices for biological products. In addition, revised WHO Recommendations to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines were also adopted by the Committee. Subsequent sections of the report provide information on the current status and proposed development of international reference materials in the areas of antibiotics; biotherapeutics other than blood products; blood products and related substances; in vitro diagnostic device reagents; and vaccines and related substances. A series of annexes are then presented which include an updated list of all WHO Recommendations, Guidelines and other documents on biological substances used in medicine (Annex 1). The above four WHO documents adopted on the advice of the Committee are then published as part of this report (Annexes 2–5). Finally, all additions and discontinuations made during the 2015 meeting to the list of International Standards, Reference Reagents and Reference Panels for biological substances maintained by WHO are summarized in Annex 6. The updated full catalogue of WHO International Reference Preparations is available at: http://www.who.int/bloodproducts/catalogue/en/.
本报告介绍了世界卫生组织(WHO)一个专家委员会的建议。该委员会受委托协调相关活动,以推动通过关于疫苗和其他生物制品生产与控制的国际建议,并建立国际生物参考物质。在简短的引言之后,报告总结了提请委员会关注的一些一般性问题。报告的下一部分对制造商和国家监管当局尤为重要,概述了就制定和通过新的及修订后的WHO建议、指南和指导文件所进行的讨论。经过这些讨论,通过了一份关于已批准的重组DNA衍生生物治疗药物监管评估的WHO指导文件,以及关于在扩展的控制温度条件下使用的疫苗稳定性评估和WHO生物制品良好生产规范的指南。此外,委员会还通过了修订后的WHO建议,以确保重组人乳头瘤病毒病毒样颗粒疫苗的质量、安全性和有效性。报告的后续章节提供了抗生素、血液制品以外的生物治疗药物、血液制品及相关物质、体外诊断设备试剂、疫苗及相关物质等领域国际参考物质的现状和拟议发展情况的信息。随后列出了一系列附件,其中包括所有WHO关于医学中使用的生物物质的建议、指南和其他文件的更新清单(附件1)。根据委员会的建议通过的上述四份WHO文件作为本报告的一部分予以发布(附件2 - 5)。最后,附件6总结了2015年会议期间对WHO维护的生物物质国际标准、参考试剂和参考专家组清单所做的所有新增和停用内容。WHO国际参考制剂的更新完整目录可在以下网址获取:http://www.who.int/bloodproducts/catalogue/en/ 。